Tango Therapeutics

Yahoo Finance • 11 days ago

Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase

On May 15, 2026, Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals(NASDAQ:CRVS), acquiring 1,100,000 shares in the first quarter for an estimated $17.55 million based on quarterly average pricing. What happened... Full story

Yahoo Finance • 11 days ago

Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally

Boxer Capital Management increased its stake in Kodiak Sciences(NASDAQ:KOD) during the first quarter, adding 225,000 shares in a transaction estimated at $5.81 million based on quarterly average pricing, according to a May 15, 2026, SEC fi... Full story

Yahoo Finance • 11 days ago

Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares

On May 15, 2026, Boxer Capital Management disclosed a purchase of 1,241,000 Vir Biotechnology(NASDAQ:VIR) shares, an estimated $9.89 million trade based on quarterly average pricing. What happened According to a Securities and Exchange C... Full story

Yahoo Finance • 12 days ago

Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy

What happened According to an SEC filing dated May 15, 2026, Acuta Capital Partners, LLC initiated a new position in Erasca(NASDAQ:ERAS) during the first quarter. The fund acquired 354,575 shares, with an estimated transaction value of $4... Full story

Yahoo Finance • 15 days ago

Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

First clinical data from PRMT5/RAS(ON) combination trial to be presented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points BOSTON, May 13, 2026 (GLOBE NEWSWI... Full story

Yahoo Finance • 17 days ago

Stifel Remains Bullish on Tango Therapeutics (TNGX)

Tango Therapeutics, Inc. (NASDAQ:TNGX) is one of the best performing healthcare stocks so far in 2026. Stifel lifted the price target on Tango Therapeutics, Inc. (NASDAQ:TNGX) to $40 from $24 on April 27, maintaining a Buy rating on the sh... Full story

Yahoo Finance • 24 days ago

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that effective May 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted (i) a non-qualified stock option t... Full story

Yahoo Finance • 2 months ago

Tango Therapeutics President Sells 27,000 Shares for $572,000 as Share Price Skyrockets

Crystal Adam, President of R&D at Tango Therapeutics(NASDAQ:TNGX), reported the exercise of 27,000 stock options -- with the underlying common shares immediately sold for approximately $572,000 -- according to an SEC Form 4 filing on April... Full story

Yahoo Finance • 2 months ago

Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day Surge

Key Points Adam Crystal sold 20,251 shares for a transaction value of ~$304,000 on March 5, 2026, at an average price of around $15 per share. This sale represented 15.24% of Crystal's direct holdings, reducing his directly held position... Full story

Yahoo Finance • 2 months ago

The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology

VANCOUVER, British Columbia, March 19, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary — Big money is moving back into biotech. Institutional investors have been writing some of the largest checks in years, with major financi... Full story

Yahoo Finance • 3 months ago

Wedbush Reaffirms Outperform Rating for Tango Therapeutics (TNGX)

Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On March 6, Wedbush increased the firm’s price target on Tango Therapeutics Inc. (NASDAQ:TNGX) from $15 to $19 following t... Full story

Yahoo Finance • 3 months ago

Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing

On February 17, 2026, Boxer Capital Management, LLC disclosed a buy of 135,000 shares of Celcuity(NASDAQ:CELC), an estimated $11.10 million trade based on quarterly average pricing. What Happened According to a February 17, 2026, SEC fil... Full story

Yahoo Finance • 3 months ago

Tango Therapeutics, Up 39% This Year, Surges Again On Another Cancer Pact

Shares of top 1% biotech stock Tango Therapeutics shot higher Thursday after the company agreed to codevelop a cancer treatment with Erasca. Continue Reading... Full story

Yahoo Finance • 3 months ago

Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing

On February 17, 2026, Boxer Capital Management, LLC disclosed a new position in Terns Pharmaceuticals(NASDAQ:TERN), acquiring 375,000 shares in a transaction estimated at $15.15 million based on quarterly average pricing. What Happened B... Full story

Yahoo Finance • 5 months ago

Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference

Tango Therapeutics Sub, Inc BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to deliver... Full story

Yahoo Finance • 6 months ago

Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

BOSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Adam Crystal, M.D., Ph.D., President of Research & Development at Tango Therapeutics, is scheduled to participate in a fireside chat... Full story

Yahoo Finance • 6 months ago

Tango Therapeutics launches $100M at-the-market stock offering

* Tango Therapeutics (TNGX [https://seekingalpha.com/symbol/TNGX]) entered [https://seekingalpha.com/filing/52044862] a sales agreement with Leerink Partners to sell up to $100M of common stock through an at-the-market offering. * Leer... Full story

Yahoo Finance • 8 months ago

Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025

BOSTON, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the... Full story

Yahoo Finance • 9 months ago

Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

BOSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at t... Full story

Yahoo Finance • 10 months ago

Tango Therapeutics Inc (NASDAQ:TNGX) Reports Q2 2025 Earnings: Revenue Misses, EPS Meets Expectations Amid Clinical Progress

TANGO THERAPEUTICS INC (NASDAQ:TNGX [https://www.chartmill.com/stock/quote/TNGX/profile]) reported its second-quarter 2025 financial results, missing revenue estimates while aligning closely with earnings per share (EPS) expectations. The... Full story